SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: In addition, the EMA and FDA have approved stiripentol and cannabidiol for the treatment of Dravet syndrome, mainly caused by variants in the SCN1A gene [38–40].